Effectiveness and Safety of Reduced-Dose Prasugrel in an East Asian Population: PRASFIT-ACS Emulation Using National Health Insurance Claims Data.

ABSTRACT: Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real-world effectiveness and safety of reduced-dose prasugrel in an East Asian population by emulating the pivotal PRASFIT-ACS trial using Taiwan's National Health Insurance claims data. In this study, ACS patients were classified into reduced-dose prasugrel or clopidogrel groups post-PCI. We estimated the intention-to-treat effect of initiating reduced-dose prasugrel vs. clopidogrel on the risk of major adverse cardiovascular events (MACE) and the per-protocol effect of treating with reduced-dose prasugr

SUBMITTER: Huang LW 

PROVIDER: S-EPMC12390784 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature